[ad_1]
Investment management company Polen Capital has released its “Polen US SMID Corporate Growth Strategy” Q4 2023 Investor Letter. You can download a copy of the same here. The portfolio’s gross return for the fourth quarter was 14.98%, or 14.65% net of fees. In comparison, the Russell 2500 Growth Index returned 12.59%. The annual portfolio return was 29.39% gross and 28.05% net, while the index return was 18.93%. Plus, check out the fund’s top 5 holdings to find out the best stocks for 2023.
Polen US SMID Company Growth Strategy’s Q4 2023 Investor Letter featured stocks such as Biotechne Corporation (NASDAQ:TECH). Bio-Techne Corporation (NASDAQ:TECH), headquartered in Minneapolis, Minnesota, is a developer and manufacturer of reagent solutions, instruments and services for the research and clinical diagnostic markets. Biotechne Corporation (NASDAQ:TECH) stock closed at $71.76 per share on February 22, 2024. Bio-Techne Corporation (NASDAQ:TECH)’s 1-month return is -1.20%, and the company’s stock has lost 0.99% of its value over the past 52 weeks. Bio-Techne Corporation (NASDAQ:TECH) has a market capitalization of $11.28 billion.
Polen US SMID Company Growth Strategy says this about Bio-Techne Corporation (NASDAQ:TECH) in its Q4 2023 Investor Letter:
“Biotechne Co., Ltd.” (NASDAQ:TECH) is a protein science/proteomics company that sells equipment and manufactures hundreds of thousands of proteins. Proteins and antibodies are used in research and increasingly in clinical practice for a wide range of treatments. Bio-Techne’s customers include large and small biopharmaceutical companies, academic research institutions, clinical laboratories, and in vitro diagnostic manufacturers. The business stands out for its strong performance over the past decade, including enhanced product differentiation, accelerated organic revenue growth and a cash flow return on invested capital (CFROIC) of more than 20%. More recently, the business has been negatively impacted by post-COVID-19 inventory reduction trends and China’s economic downturn, both of which have an impact on the life sciences industry as a whole. We believe this is a unique opportunity to invest in our high quality flywheel company. Over the long term, he is expected to have the potential to deliver earnings growth in the mid-to-high teens. Like Medpace, the company is well-positioned to benefit from some of the most important growth markets for emerging biopharmaceuticals without risking either-or outcomes or a zero-cash flow biotech business model. we believe. ”
Laboratory technician studying cell samples in a biotechnology laboratory.
Bio-Techne Corporation (NASDAQ:TECH) isn’t on the list of 30 most popular stocks among hedge funds. Our database shows that Biotechne Corporation (NASDAQ:TECH) was held by 23 hedge fund portfolios at the end of the fourth quarter, down from 25 at the prior quarter.
We discussed Bio-Techne Corporation (NASDAQ:TECH) in a separate article and shared Alger Small Cap Growth Fund’s view on the company. Additionally, for investor letters from hedge funds and other leading investors, please visit our Hedge Fund Investor Letters Q4 2023 page.
Recommended articles:
Disclosure: None. This article was originally published on Insider Monkey.
[ad_2]
Source link
